PDGF receptors as targets in tumor treatment
2007 (English)In: Advances in Cancer Research, ISSN 0065-230X, Vol. 97, 247-274 p.Article, review/survey (Refereed) Published
Signaling through platelet-derived growth factor (PDGF) receptors contributes to multiple tumor-associated processes. The recent introduction of clinically useful PDGF inhibitors have the last years validated PDGF receptors in malignant and stromal cells as relevant cancer drug targets. Mutational activation of PDGF receptor signaling in malignant cells has been described in some rare tumor types such as dermatofibrosarcoma protuberans, a subset of GISTs, and some hematologic malignancies. Furthermore, expression of PDGF receptors on pericytes is a common characteristic of solid tumors. The clinical efficacy of novel multikinase inhibitors, such as sunitimb and sorafemb, most likely involves targeting of PDGF receptor-dependent pericytes. Preclinical studies suggest that targeting of stromal PDGF receptors might also constitute a novel strategy to enhance tumor drug uptake. Finally, recent studies have implied both pro- and antimetastatic effects of PDGF receptors on malignant and stromal cells. The studies on the roles of PDGF receptors in cancer signaling are thus presently in a dynamic phase where collaborations between oncologists, pathologists, and tumor biologists are predicted to be highly productive.
Place, publisher, year, edition, pages
San Diego: Academic Press , 2007. Vol. 97, 247-274 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-12891DOI: 10.1016/S0065-230X(06)97011-0ISI: 000245920000011ISBN: 978-0-12-006697-1OAI: oai:DiVA.org:uu-12891DiVA: diva2:40661